Survivin and CrkL expression in erlotinib-treated non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations.

e18063 Background: Survivin inhibits activation of caspas es, and its overexpr ession can lead to resistance to apoptotic stimuli. Enhanced survivin expression has been shown to be related to IGF-1...